Prognostic and predictive factors of eribulin efficacy in heavily pretreated patients affected by metastatic breast cancer: correlation with tumor biology and previous therapies

BACKGROUND: Eribulin mesylate is currently approved in the United States and Europe for the treatment of metastatic breast cancer (MBC). SCOPE: The objective of this retrospective study is to find specific predictive criteria related to patient or tumor characteristics in order to select patients th...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Sabrina, Cassano, Alessandra, Strippoli, Antonia, Schinzari, Giovanni, D’Argento, Ettore, Basso, Michele, Barone, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioExcel Publishing Ltd 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699107/
https://www.ncbi.nlm.nih.gov/pubmed/29167692
http://dx.doi.org/10.7573/dic.212506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5699107/
https://www.ncbi.nlm.nih.gov/pubmed/29167692
http://dx.doi.org/10.7573/dic.212506

Ejemplares similares